Paxil makers failed to disclose information

GlaxoSmithKline, the maker of the antidepressant Paxil, failed to disclose information about the possibility of a risk of suicidal behavior in children taking the drug, as well as withdrawal symptoms when some patients stop taking Paxil.Earlier this year, the Food and Drug Administration ordered manufacturers to place a warning on antidepressants, pointing that the drugs can cause suicidal tendencies in children.Internal studies of GlaxoSmithKline reports, that some children showed the some types of suicidal thoughts and behaviors. The studies concluded that Paxil had little or no effect in treating depression in children and adolescents.Additionally, the internal report reveals that Paxil could cause mild to severe withdrawal symptoms in some patients when they stopped taking the drug. The documents suggest GlaxoSmithKline's sales strategy was to downplay this information.